{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:34:32Z","timestamp":1790091272719,"version":"4.0.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Suzetrigine, a novel nonopioid analgesic, selectively inhibits voltage-gated sodium channel 1.8 (NaV1.8) and has recently been approved for the management of moderate to severe acute pain. This meta-analysis aimed to evaluate the efficacy and safety of suzetrigine by cumulating data from available evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A literature search was conducted using ClinicalTrials.gov, PubMed, and Cochrane Central Register of Controlled Trials. Five randomized controlled trials (RCTs) were included in the systematic review, with four RCTs in the meta-analysis. The primary efficacy outcomes were time-weighted sum of pain intensity difference over 48 h (SPID 48) and 24 h (SPID 24) between suzetrigine and placebo. Secondary outcomes included proportion of participants achieving \u226530%, \u226550%, and \u226570% reduction in numeric pain rating scale (NPRS) scores at 48 h and safety analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Suzetrigine showed significantly better efficacy versus placebo in reducing pain, with a standard mean difference of 5.55 (95% CI 2.97-8.13,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.00001) for SPID 48 and 5.33 (95% CI 2.50-8.16,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.00001) for SPID 24. Odds of achieving \u226530%, \u226550%, and \u226570% reduction in NPRS scores at 48 h were significantly higher in the suzetrigine group (OR 1.95, 1.74, and 1.81, respectively; all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.00001). Suzetrigine showed comparable efficacy to hydrocodone bitartrate-acetaminophen (HB\/APAP) with a better safety profile, showing lower incidence of adverse events and gastrointestinal side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Suzetrigine appears to be an effective, well-tolerated option for acute pain management, showing superiority to placebo and comparable efficacy to HB\/APAP, with a better safety profile. However, future long-term studies are needed to assess its efficacy and safety in various acute pain settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sja.sja_602_25","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:00:52Z","timestamp":1767337252000},"page":"82-91","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Selective Nav1.8 inhibition by suzetrigine, a novel nonopioid analgesic for acute pain management: A systematic review and metanalysis"],"prefix":"10.4103","volume":"20","author":[{"given":"Sumit","family":"Bansal","sequence":"first","affiliation":[{"name":"Department of Anaesthesia, AIIMS, Rajkot, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunit Kumar","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, AIIMS, Mangalagiri, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, AIIMS, Rajkot, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima B.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, AIIMS, Rajkot, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubha","family":"Singhal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, AIIMS, Rajkot, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"R1-20260421","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1002\/bjs.11477","article-title":"Acute postoperative pain management","volume":"107","author":"Small","year":"2020","journal-title":"Br J Surg"},{"key":"R2-20260421","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2147\/JPR.S144066","article-title":"Poorly controlled postoperative pain: Prevalence, consequences, and prevention","volume":"10","author":"Gan","year":"2017","journal-title":"J Pain Res"},{"key":"R3-20260421","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12871-020-01147-y","article-title":"Efficacy of non-opioid analgesics to control postoperative pain: A network meta-analysis","volume":"20","author":"Carter","year":"2020","journal-title":"BMC Anesthesiol"},{"key":"R4-20260421","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/ph14111091","article-title":"Opioid analgesia and opioid-induced adverse effects: A review","volume":"14","author":"Paul","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"R5-20260421","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther"},{"key":"R6-20260421","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40265-025-02178-w","article-title":"Suzetrigine: First Approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"R7-20260421","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R8-20260421","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias visualization (robvis): An R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"key":"R9-20260421","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV1.8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"N Engl J Med"},{"key":"R10-20260421","first-page":"1085","article-title":"Suzetrigine, a nonopioid Na V 1.8 inhibitor for treatment of moderate-to-severe acute pain: Two phase 3 randomized clinical trials","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"key":"R11-20260421","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: A phase 3 single-arm study for surgical or non-surgical acute pain","volume":"18","author":"McCoun","year":"2025","journal-title":"J Pain Res"},{"key":"R12-20260421","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/j.pain.0000000000002736","article-title":"Abdominoplasty as an acute postoperative pain model: Insights from 8 years of clinical trials","volume":"164","author":"Singla","year":"2023","journal-title":"Pain"},{"key":"R13-20260421","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.2147\/JPR.S466723","article-title":"Bunionectomy as an acute postoperative pain model: Overview of common experimental methods, and insights from past clinical trials","volume":"17","author":"Singla","year":"2024","journal-title":"J Pain Res"},{"key":"R15-20260421","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijsu.2020.08.033","article-title":"Effects of virtual reality on relieving postoperative pain in surgical patients: A systematic review and meta-analysis","volume":"82","author":"Ding","year":"2020","journal-title":"Int J Surg"},{"key":"R16-20260421","doi-asserted-by":"crossref","first-page":"99","DOI":"10.28982\/josam.7774","article-title":"The effect of postoperative pain on comfort in patients undergoing abdominal surgery","volume":"8","author":"Soysal","year":"2024","journal-title":"J Surg Med"},{"key":"R17-20260421","doi-asserted-by":"crossref","first-page":"102433","DOI":"10.1016\/j.coph.2024.102433","article-title":"Analgesic potential of voltage gated sodium channel modulators for the management of pain","volume":"75","author":"McDougall","year":"2024","journal-title":"Curr Opin Pharmacol"},{"key":"R18-20260421","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.2147\/JPR.S526851","article-title":"Suzetrigine approval breaks a 25-year silence: A new era in non-opioid acute pain management","volume":"18","author":"Sibomana","year":"2025","journal-title":"J Pain Res"},{"key":"R19-20260421","first-page":"104","article-title":"Suzetrigine, a selective pain signal inhibitor of NaV1.8 shows proof-of-concept for treatment of painful diabetic peripheral neuropathy (S11.002)","author":"Freeman","year":"2024","journal-title":"Neurology"}],"container-title":["Saudi Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sja.sja_602_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:48Z","timestamp":1786647588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sja.sja_602_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/sja.sja_602_25","relation":{},"ISSN":["1658-354X","0975-3125"],"issn-type":[{"value":"1658-354X","type":"print"},{"value":"0975-3125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-07-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}